Mainz Biomed (MYNZ) Projected to Post Earnings on Tuesday

Mainz Biomed (NASDAQ:MYNZ) is expected to be announcing its H2 2025 resultson Tuesday, April 14th. Analysts expect the company to announce earnings of ($1.01) per share and revenue of $0.67 million for the quarter. Investors are encouraged to explore the company’s upcoming H2 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 7:00 AM ET.

Mainz Biomed Trading Down 4.0%

Shares of Mainz Biomed stock opened at $0.46 on Tuesday. The company has a market capitalization of $4.15 million, a P/E ratio of -0.01 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. The company has a fifty day moving average of $0.78 and a 200 day moving average of $1.12. Mainz Biomed has a fifty-two week low of $0.55 and a fifty-two week high of $5.34.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on MYNZ shares. Maxim Group downgraded shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Weiss Ratings reiterated a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Trading of Mainz Biomed

Several hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC lifted its stake in Mainz Biomed by 96.5% in the 4th quarter. Armistice Capital LLC now owns 775,263 shares of the company’s stock worth $868,000 after purchasing an additional 380,744 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Mainz Biomed by 200.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in Mainz Biomed in the 4th quarter worth $183,000.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.